Crossmark

Long-term clinical outcomes of certolizumab pegol treatment in non-radiographic axial spondyloarthritis stratified by baseline MRI and CRP status

Crossref DOI link: https://doi.org/10.1136/rmdopen-2023-003884

Published Online: 2024-05-09

Published Print: 2024-05

Update policy: https://doi.org/10.1136/crossmarkpolicy

Authors

Rudwaleit, Martin https://orcid.org/0000-0001-5445-548X
Deodhar, Atul

Bauer, Lars

Gensler, Lianne

Hoepken, Bengt

Kumke, Thomas

Auteri, Simone Emanuele

Kim, Mindy

Maksymowych, Walter https://orcid.org/0000-0002-1291-1755
Clinical Trials ^BETA

Clinical trials referenced in this document:

nct02552212 at ClinicalTrials.gov

Documents that mention this clinical trial

POS0896 PREDICTORS OF RESPONSE IN PATIENTS WITH NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS RECEIVING CERTOLIZUMAB PEGOL IN THE C-AXSPAND STUDY
https://doi.org/10.1136/annrheumdis-2021-eular.108

FRI0408 EARLIER TREATMENT OF NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS WITH CERTOLIZUMAB PEGOL RESULTS IN IMPROVED CLINICAL OUTCOMES
https://doi.org/10.1136/annrheumdis-2019-eular.790

Long-term clinical outcomes of certolizumab pegol treatment in non-radiographic axial spondyloarthritis stratified by baseline MRI and CRP status
https://doi.org/10.1136/rmdopen-2023-003884

POS0941 LONG-TERM CLINICAL OUTCOMES OF CERTOLIZUMAB PEGOL TREATMENT IN PATIENTS WITH ACTIVE NON‑RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS STRATIFIED BY BASELINE MRI AND C-REACTIVE PROTEIN STATUS
https://doi.org/10.1136/annrheumdis-2022-eular.2834

Long-term safety and clinical outcomes of certolizumab pegol treatment in patients with active non-radiographic axial spondyloarthritis: 3-year results from the phase 3 C-axSpAnd study
https://doi.org/10.1136/rmdopen-2021-002138

nct02552212 at ClinicalTrials.gov

Documents that mention this clinical trial

POS0896 PREDICTORS OF RESPONSE IN PATIENTS WITH NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS RECEIVING CERTOLIZUMAB PEGOL IN THE C-AXSPAND STUDY
https://doi.org/10.1136/annrheumdis-2021-eular.108

FRI0408 EARLIER TREATMENT OF NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS WITH CERTOLIZUMAB PEGOL RESULTS IN IMPROVED CLINICAL OUTCOMES
https://doi.org/10.1136/annrheumdis-2019-eular.790

Long-term clinical outcomes of certolizumab pegol treatment in non-radiographic axial spondyloarthritis stratified by baseline MRI and CRP status
https://doi.org/10.1136/rmdopen-2023-003884

POS0941 LONG-TERM CLINICAL OUTCOMES OF CERTOLIZUMAB PEGOL TREATMENT IN PATIENTS WITH ACTIVE NON‑RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS STRATIFIED BY BASELINE MRI AND C-REACTIVE PROTEIN STATUS
https://doi.org/10.1136/annrheumdis-2022-eular.2834

Long-term safety and clinical outcomes of certolizumab pegol treatment in patients with active non-radiographic axial spondyloarthritis: 3-year results from the phase 3 C-axSpAnd study
https://doi.org/10.1136/rmdopen-2021-002138

nct02552212 at ClinicalTrials.gov

Documents that mention this clinical trial

POS0896 PREDICTORS OF RESPONSE IN PATIENTS WITH NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS RECEIVING CERTOLIZUMAB PEGOL IN THE C-AXSPAND STUDY
https://doi.org/10.1136/annrheumdis-2021-eular.108

FRI0408 EARLIER TREATMENT OF NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS WITH CERTOLIZUMAB PEGOL RESULTS IN IMPROVED CLINICAL OUTCOMES
https://doi.org/10.1136/annrheumdis-2019-eular.790

Long-term clinical outcomes of certolizumab pegol treatment in non-radiographic axial spondyloarthritis stratified by baseline MRI and CRP status
https://doi.org/10.1136/rmdopen-2023-003884

POS0941 LONG-TERM CLINICAL OUTCOMES OF CERTOLIZUMAB PEGOL TREATMENT IN PATIENTS WITH ACTIVE NON‑RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS STRATIFIED BY BASELINE MRI AND C-REACTIVE PROTEIN STATUS
https://doi.org/10.1136/annrheumdis-2022-eular.2834

Long-term safety and clinical outcomes of certolizumab pegol treatment in patients with active non-radiographic axial spondyloarthritis: 3-year results from the phase 3 C-axSpAnd study
https://doi.org/10.1136/rmdopen-2021-002138

nct02552212 at ClinicalTrials.gov

Documents that mention this clinical trial

POS0896 PREDICTORS OF RESPONSE IN PATIENTS WITH NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS RECEIVING CERTOLIZUMAB PEGOL IN THE C-AXSPAND STUDY
https://doi.org/10.1136/annrheumdis-2021-eular.108

FRI0408 EARLIER TREATMENT OF NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS WITH CERTOLIZUMAB PEGOL RESULTS IN IMPROVED CLINICAL OUTCOMES
https://doi.org/10.1136/annrheumdis-2019-eular.790

Long-term clinical outcomes of certolizumab pegol treatment in non-radiographic axial spondyloarthritis stratified by baseline MRI and CRP status
https://doi.org/10.1136/rmdopen-2023-003884

POS0941 LONG-TERM CLINICAL OUTCOMES OF CERTOLIZUMAB PEGOL TREATMENT IN PATIENTS WITH ACTIVE NON‑RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS STRATIFIED BY BASELINE MRI AND C-REACTIVE PROTEIN STATUS
https://doi.org/10.1136/annrheumdis-2022-eular.2834

Long-term safety and clinical outcomes of certolizumab pegol treatment in patients with active non-radiographic axial spondyloarthritis: 3-year results from the phase 3 C-axSpAnd study
https://doi.org/10.1136/rmdopen-2021-002138
Funding

Funding for this research was provided by:

UCB Pharma
License Information

License valid from 2024-05-09

Document is current

Any future updates will be listed below